Efficacy and safety of fluvoxamine in body dysmorphic disorder.
- 15 April 1998
- journal article
- clinical trial
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 59 (4) , 165-171
- https://doi.org/10.4088/jcp.v59n0404
Abstract
Body dysmorphic disorder (BDD), a preoccupation with an imagined or slight defect in appearance, has been noted in case reports, retrospective studies, and clinical series to respond to serotonin reuptake inhibitors (SRIs). These data further suggest that the delusional variant of BDD (delusional disorder, somatic type) may also respond to SRIs. However, systematic pharmacologic treatment studies of BDD and its delusional variant are needed.Keywords
This publication has 0 references indexed in Scilit: